It is understood that provides an EphA4 Antibody or a fragment of this Union to EphA4 that EphA4 is able to bind to and inhibit the Union between EphA4 and its ligand, and a Pharmaceutical composition comprising the EphA4 Antibody or Fragment of EphA4 as a Union of the ingredi Active entity.EphA4 Antibody was a Mouse that has binding Affinity by EphA4 and identified sequences of the complementarity determining Regions (CDR) of the Antibody of Mouse anti EphA4.This allowed the preparation of a Humanized Antibody that includes CDR sequences of EphA4 Antibody anti mouse in the variable regions of the heavy chain and light chain.Claim 1: EphA4 Antibody or a fragment of this Union to EphA4.That includes (a) CDR H1 - comprising the Amino Acid Sequence represented by SEQ ID no. 26 or SEQ ID no. 27； (b) cor - H2 comprising the Amino Acid Sequence represented by SEQ ID no. 28 or SEQ ID no. 29； (c) CDR H3 comprising the Amino Acid Sequence represented by the S EQ id no. 30； (d) cor - L1 comprising the Amino Acid Sequence represented by SEQ ID no. 31； (e) CDRL2 - comprising the Amino Acid Sequence represented by SEQ ID no. 32； and (f) CDR L3 comprising the Amino Acid Sequence represented by SEQ ID no. 33.Se entiende que proporciona un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 de este que es capaz de unirse a EphA4 e inhibir la unión entre EphA4 y su ligando, y una composición farmacéutica que comprende el anticuerpo anti-EphA4 o el fragmento de unión a EphA4 de este como un ingrediente activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión por EphA4 y se identificaron las secuencias de las regiones determinantes de complementariedad (CDR) del anticuerpo anti-EphA4 de ratón. Esto permitió la preparación de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo anti-EphA4 de ratón en las regiones variables de la cadena pesada y cadena liviana. Reivindicación 1: Un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 de e
